The current standard therapy for acute-phase Guillain-Barré syndrome (GBS) remains limited to intravenous immunoglobulin and plasma exchange. Developing novel pharmacological agents to halt acute disease progression represents a critical unmet need. 4-Octyl i... ...

请注册登录后继续浏览